In our study, TP53 abnormalities (mutation and/or deletion) occurred in 23/69 (33.3%) samples, with a significant prevalence of both gene mutation (p = 0.0016) and allelic loss (p = 0.0048) in astrocytomas, when compared to the other histological groups, confirming previous reports [21,22]. The gene discussed is TP53; the disease is astrocytoma (excluding glioblastoma).